Literature DB >> 7841156

Anxiety, depression, psychosomatic symptoms and autonomic nervous function in patients with chronic urticaria.

M Hashiro1, M Okumura.   

Abstract

Most reports on the psychological analysis of chronic urticaria have concentrated on psychodynamic theories of causation of the disease. For the present study, we used three kinds of psychological tests as well as electrocardiography to estimate anxiety, depressiveness, psychosomatic symptoms and autonomic nervous functions in 30 outpatients with chronic urticaria and 39 normal controls. For evaluation we used the manifest anxiety scale (MAS), self-rating depression scale (SDS), Cornell medical index (CMI) and convergence of variance of R-R interval (CVR-R). Psychologically positive responses to any one of the tests were seen in 70.0% of the chronic urticaria patients, but in only 25.6% of the controls. These differences all showed statistical significance (P < 0.01). The In(CVR-R) (Y) and age (X) suggested a linear regression, but although the regression slope was steeper for the urticaria group (Y = 2.924-0.027X) than for the controls (Y = 2.702-0.023X), the difference was not statistically significant. These data indicate that patients with chronic urticaria are more anxious, depressive and psychosomatic symptom-prone than normal controls. In conclusion, we suggest that chronic urticaria patients should be diagnosed and treated both dermatologically and psychologically.

Entities:  

Mesh:

Year:  1994        PMID: 7841156     DOI: 10.1016/0923-1811(94)90007-8

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  10 in total

Review 1.  Psychocutaneous disorders.

Authors:  D G Folks; J K Warnock
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

Review 2.  [Selected psychosomatic aspects of dermatologic practice].

Authors:  A Stumpf
Journal:  Hautarzt       Date:  2012-10       Impact factor: 0.751

3.  Specificity in the association of anxiety, depression, and atopic disorders in a community sample of adolescents.

Authors:  Marcia J Slattery; Marilyn J Essex
Journal:  J Psychiatr Res       Date:  2010-11-25       Impact factor: 4.791

4.  Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria.

Authors:  Laura Diluvio; Arianna Piccolo; Francesco Marasco; Laura Vollono; Caterina Lanna; Barbara Chiaramonte; Cinzia Niolu; Elena Campione; Luca Bianchi
Journal:  Future Sci OA       Date:  2020-08-10

5.  Psychodermatology: a guide to understanding common psychocutaneous disorders.

Authors:  Mohammad Jafferany
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

6.  Relevance of psychiatry in dermatology: Present concepts.

Authors:  K H Basavaraj; M A Navya; R Rashmi
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

7.  Temperament and character profiles of patients with chronic idiopathic urticaria.

Authors:  Sevil Alan; Fatih Canan; Ayşe Akman Karakaş; Nihal Geçici
Journal:  Postepy Dermatol Alergol       Date:  2015-06-10       Impact factor: 1.837

8.  Sense of coherence as a protective factor in chronic urticaria.

Authors:  Alicja Ograczyk; Joanna Miniszewska; Anna Pietrzak; Anna Zalewska-Janowska
Journal:  Postepy Dermatol Alergol       Date:  2017-04-13       Impact factor: 1.837

9.  Association of atopic dermatitis with depressive symptoms and suicidal behaviors among adolescents in Korea: the 2013 Korean Youth Risk Behavior Survey.

Authors:  Seulki Lee; Aesun Shin
Journal:  BMC Psychiatry       Date:  2017-01-03       Impact factor: 3.630

10.  Epidemiology of urticaria in China: a population-based study.

Authors:  Jiaqing Li; Dandan Mao; Shuoshuo Liu; Ping Liu; Jing Tian; Chenhong Xue; Xiaojing Liu; Ruiqun Qi; Bingxue Bai; Jianjun Nie; Siqi Ye; Yu Wang; Yuye Li; Qing Sun; Juan Tao; Shuping Guo; Hong Fang; Jianqin Wang; Qiri Mu; Quanzhong Liu; Yan Ding; Jianzhong Zhang
Journal:  Chin Med J (Engl)       Date:  2022-06-05       Impact factor: 6.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.